This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Evolving paradigms in the treatment of relapsed/refractory multiple myeloma: increased options and increased complexity
Bone Marrow Transplantation Open Access 04 January 2016
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Dimopoulos M, Spencer A, Attal M, Prince HM, Harousseau JL, Dmoszynska A et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 2007; 357: 2123–2132.
Teo SK . Properties of thalidomide and its analogues: implications for anticancer therapy. AAPS J 2005; 7: E14–E19.
Durie BG, Harousseau JL, Miguel JS, Blade J, Barlogie B, Anderson K et al. International uniform response criteria for multiple myeloma. Leukemia 2006; 20: 1467–1473.
Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 1974; 18: 295–304.
Roncarolo MG, Gregori S . Is FOXP3 a bona fide marker for human regulatory T cells? Eur J Immunol 2008; 38: 925–927.
Rezvani K, Mielke S, Ahmadzadeh M, Kilical Y, Savani BN, Zeilah J et al. High donor FOXP3-positive regulatory T-cell (Treg) content is associated with a low risk of GVHD following HLA-matched allogeneic SCT. Blood 2006; 108: 1291–1297.
Beyer M, Kochanek M, Giese T, Endl E, Weihrauch MR, Knolle PA et al. In vivo peripheral expansion of naive CD4+CD25high FoxP3+ regulatory T cells in patients with multiple myeloma. Blood 2006; 107: 3940–3949.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Minnema, M., van der Veer, M., Aarts, T. et al. Lenalidomide alone or in combination with dexamethasone is highly effective in patients with relapsed multiple myeloma following allogeneic stem cell transplantation and increases the frequency of CD4+Foxp3+ T cells. Leukemia 23, 605–607 (2009). https://doi.org/10.1038/leu.2008.247
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2008.247
This article is cited by
-
Maintenance therapy after allogeneic hematopoietic stem cell transplantation for patients with multiple myeloma
International Journal of Hematology (2023)
-
Flow cytometry analysis of peripheral Tregs in patients with multiple myeloma under lenalidomide maintenance
International Journal of Hematology (2021)
-
Lenalidomide improves the therapeutic effect of an interferon-α-dendritic cell-based lymphoma vaccine
Cancer Immunology, Immunotherapy (2019)
-
In search of the optimal platform for Post-Allogeneic SCT immunotherapy in relapsed multiple myeloma: a systematic review
Bone Marrow Transplantation (2017)
-
Allogeneic Hematopoietic Cell Transplantation for Myeloma: When and in Whom Does It Work
Current Hematologic Malignancy Reports (2017)